E Fund Management Co., Ltd. Crinetics Pharmaceuticals, Inc. Transaction History
E Fund Management Co., Ltd.
- $2.07 Billion
- Q1 2025
A detailed history of E Fund Management Co., Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 9,545 shares of CRNX stock, worth $295,799. This represents 0.02% of its overall portfolio holdings.
Number of Shares
9,545
Previous 5,775
65.28%
Holding current value
$295,799
Previous $295,000
8.47%
% of portfolio
0.02%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding CRNX
# of Institutions
230Shares Held
87.1MCall Options Held
40KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA9.31MShares$289 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$214 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$193 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$193 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$158 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.67B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...